Skip to Content
Merck
  • Comparative in vitro activity of furopenem against aerobic bacteria isolated from pediatric patients.

Comparative in vitro activity of furopenem against aerobic bacteria isolated from pediatric patients.

Diagnostic microbiology and infectious disease (1995-07-01)
J E Mortensen, J H Egleton
ABSTRACT

The in vitro activity of the oral penem furopenem (WY-49605, 545555, SUN5555, and ALP201) was tested against clinical bacteria isolated from pediatric patients. Furopenem was compared with clarithromycin, cefpodoxime, amoxicillin, amoxicillin-clavulanate, cefaclor, cefixime, and cefuroxime. Furopenem demonstrated consistent activity against Escherichia coli [minimum inhibitory concentration (MIC90) = 1.0 microgram/ml)] Klebsiella pneumoniae (MIC90 = 2.0 micrograms/ml), Salmonella enteriditis and Shigella spp. (MIC90 = 1.0 microgram/ml), and beta-lactamase-positive or -negative Haemophilus influenzae (MIC90 = 1.0 microgram/ml) and Moraella catarrhalis (MIC90 = 1.0 microgram/ml). Furopenem was also active against a number of the Gram-positive organisms tested including methicillin-susceptible Staphylococcus aureus and penicillin-susceptible Streptococcus pneumoniae. These results suggest a potential application for this agent in the treatment of children as outpatients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Faropenem sodium hydrate, ≥98% (HPLC)